Biotechnology annual review最新文献_第4页

Clinical trial registries and clinical trial result posting: new paradigm for medical writers. 临床试验注册和临床试验结果发布:医学作家的新范式。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12011-6

MaryAnn Foote

引用次数: 1

Recent developments in biodegradable synthetic polymers. 生物可降解合成聚合物的最新进展。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12009-8

Pathiraja Gunatillake, Roshan Mayadunne, Raju Adhikari

{"title":"Recent developments in biodegradable synthetic polymers.","authors":"Pathiraja Gunatillake, Roshan Mayadunne, Raju Adhikari","doi":"10.1016/S1387-2656(06)12009-8","DOIUrl":"https://doi.org/10.1016/S1387-2656(06)12009-8","url":null,"abstract":"This chapter reviews recent developments in biodegradable synthetic polymers focusing on tailoring polymer structures to meet material specification for emerging applications such as tissue engineered products and therapies. Major classes and new families of synthetic polymers are discussed with regard to synthesis, properties and biodegradability, and known degradation modes and products are summarized based on studies reported during the past 10-15 years. Polyesters and their copolymers, polyurethanes, polyphosphazenes, polyanhydrides, polycarbonates, polyesteramides and recently developed injectable polymer systems based on polypropylenefumarates, polyurethanes and acrylate/urethane systems are reviewed. Polyesters such as polyglycolides, polylactides and their copolymers still remain as the major class of synthetic biodegradable polymers with products in clinical use. Although various copolymerization methods have addressed needs of different applications, release of acidic degradation products, processing difficulties and limited range of mechanical properties remains as major disadvantages of this family of polymers. Injectable polymers based on urethane and urethane/acrylate have shown great promise in developing delivery systems for tissue engineered products and therapies.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1387-2656(06)12009-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26368700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 340

Emerging options in protein bioseparation. 蛋白质生物分离的新选择。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12001-3

Kalyani Mondal, Sulakshana Jain, Sunita Teotia, Munishwar N Gupta

引用次数: 18

Inhibitors of signal transduction protein kinases as targets for cancer therapy. 信号转导蛋白激酶抑制剂作为癌症治疗的靶点。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12006-2

Theresa Mikalsen, Nancy Gerits, Ugo Moens

{"title":"Inhibitors of signal transduction protein kinases as targets for cancer therapy.","authors":"Theresa Mikalsen, Nancy Gerits, Ugo Moens","doi":"10.1016/S1387-2656(06)12006-2","DOIUrl":"https://doi.org/10.1016/S1387-2656(06)12006-2","url":null,"abstract":"Cancer development requires that tumour cells attain several capabilities, including increased replicative potentials, anchorage and growth-factor independency, evasion of apoptosis, angiogenesis and metastasis. Many of these processes involve the actions of protein kinases, which have emerged as key regulators of all aspects of neoplasia. Perturbed protein kinase activity is repeatedly found to be associated with human malignancies, making these proteins attractive targets for anti-cancer therapy. The last decade has witnessed an exponential increase in the development of specific small protein kinase inhibitors. Many of them are in clinical trials in patients with different types of cancer and some are successfully used in clinic. This review describes different approaches that are currently applied to develop such specific protein kinase inhibitors and provides an overview of protein kinase inhibitors that are currently in clinical trials or are administered in the clinic. Focus is directed on inhibitors against receptor tyrosine kinases and protein kinases participating in the signalling cascades.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1387-2656(06)12006-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26368768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Coencapsulation of hepatocytes and bone marrow cells: in vitro and in vivo studies. 肝细胞和骨髓细胞的共囊化:体外和体内研究。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12005-0

Zun Chang Liu, Thomas Ming Swi Chang

{"title":"Coencapsulation of hepatocytes and bone marrow cells: in vitro and in vivo studies.","authors":"Zun Chang Liu, Thomas Ming Swi Chang","doi":"10.1016/S1387-2656(06)12005-0","DOIUrl":"https://doi.org/10.1016/S1387-2656(06)12005-0","url":null,"abstract":"Bioencapsulation of cells is one of the many areas of artificial cells being extensively investigated by centers around the world. This includes the bioencapsulation of hepatocytes. A number of methods have been developed to maintain the specific function and phenotype of the bioencapsulated hepatocytes for in vitro and in vivo applications. These include supplementation of factors in the culture medium; use of appropriate substrates and the co-cultivation of hepatocytes with other type of cells, the so called \"feeder cells\". These feeder cells can be of liver origin or non-liver origin. We have recently studied the role of bone marrow cells in the maintenance of hepatocytes viability and phenotype by using the coculture of hepatocytes with bone marrow cells (nucleated cells including stem cells), and the coencapsulation of hepatocytes with bone marrow stem cells. This way, the hepatocytes viability and specific function can be maintained significantly longer. In vivo studies of both syngeneic and xenogeneic transplantation show that the hepatocytes viability can be maintained longer when coencapsulated with bone marrow cells. Transplantation of coencapsulated hepatocytes and bone marrow cells enhances the ability of the hepatocytes in correcting congenital hyperbilirubinmia in Gunn rats. Both in vitro and in vivo studies show that bone marrow cells can enhance the viability and phenotype maintenance of hepatocytes. Thus, bone marrow cells play an important role as a new type of feeder cells for bioencapsulated hepatocytes for the cellular therapy of liver diseases.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1387-2656(06)12005-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26368767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Medical writing departments in biopharma companies: how to establish a department. 生物制药公司的医学写作部门:如何建立一个部门。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12012-8

MaryAnn Foote, Karen Soskin

引用次数: 0

Putting the 'Ome' in lipid metabolism. 将“Ome”放入脂质代谢中。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12003-7

David M Mutch, Laetitia Fauconnot, Martin Grigorov, Laurent B Fay

{"title":"Putting the 'Ome' in lipid metabolism.","authors":"David M Mutch, Laetitia Fauconnot, Martin Grigorov, Laurent B Fay","doi":"10.1016/S1387-2656(06)12003-7","DOIUrl":"https://doi.org/10.1016/S1387-2656(06)12003-7","url":null,"abstract":"The recognition that altered lipid metabolism underlies many metabolic disorders challenging Western society highlights the importance of this metabolomic subset, herein referred to as the lipidome. Although comprehensive lipid analyses are not a recent concept, the novelty of a lipidomic approach lies with the application of robust statistical algorithms to highlight subtle, yet significant, changes in a population of lipid molecules. First-generation lipidomic studies have demonstrated the sensitivity of interpreting quantitative datasets with computational software; however, the innate power of comprehensive lipid profiling is often not exploited, as robust statistical models are not routinely utilized. Therefore, the current review aims to briefly describe the current technologies suitable for comprehensive lipid analysis, outline innovative mathematical models that have the ability to reveal subtle changes in metabolism, which will ameliorate our understanding of lipid biochemistry, and demonstrate the biological revelations found through lipidomic approaches and their potential implications for health management.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1387-2656(06)12003-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26368765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Bleaching with lignin-oxidizing enzymes. 用木质素氧化酶漂白。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12010-4

Pratima Bajpai, Aradhna Anand, Pramod K Bajpai

{"title":"Bleaching with lignin-oxidizing enzymes.","authors":"Pratima Bajpai, Aradhna Anand, Pramod K Bajpai","doi":"10.1016/S1387-2656(06)12010-4","DOIUrl":"https://doi.org/10.1016/S1387-2656(06)12010-4","url":null,"abstract":"General concern about the environmental impact of chlorine bleaching effluents has led to a trend towards elementary chlorine-free or totally chlorine free bleaching methods. Considerable interest has been focused on the use of biotechnology in pulp bleaching, as large number of microbes and the enzymes produced by them are known to be capable of preferential degradation of native lignin and complete degradation of wood. Enzymes of the hemicellulolytic type, particularly xylan-attacking enzymes xylanases are now used commercially in the mills for pulp treatment and subsequent incorporation into bleach sequences. Certain white-rot fungi can delignify Kraft pulps increasing their brightness and their responsiveness to brightening with chemicals. The fungal treatments are too slow but the enzymes produced from the fungi can also delignify pulps and these enzymatic processes are likely to be easier to optimize and apply than the fungal treatments. This article presents an overview of the developments in the application of lignin-oxidizing enzymes in bleaching of chemical pulps. The present knowledge of the mechanisms on the action of enzymes as well as the practical results and advantages obtained on the laboratory and industrial scale are discussed.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1387-2656(06)12010-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26368701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 64

Molecularly imprinted materials as advanced excipients for drug delivery systems. 分子印迹材料作为药物输送系统的高级赋形剂。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12007-4

Carmen Alvarez-Lorenzo, Angel Concheiro

{"title":"Molecularly imprinted materials as advanced excipients for drug delivery systems.","authors":"Carmen Alvarez-Lorenzo, Angel Concheiro","doi":"10.1016/S1387-2656(06)12007-4","DOIUrl":"https://doi.org/10.1016/S1387-2656(06)12007-4","url":null,"abstract":"The application of the molecular imprinting technology in the design of new drug delivery systems (DDS) and devices useful in closely related fields, such as diagnostic sensors or biological traps, is receiving increasing attention. Molecular imprinting technology can provide polymeric materials with the ability to recognize specific bioactive molecules and with a sorption/release behaviour that can be made sensitive to the properties of the surrounding medium. In this review, an introduction to the imprinting technology presenting the different approaches in preparing selective polymers of different formats is given, and the key factors involved in obtaining of imprinted binding sites in materials useful for pharmaceutical applications are analysed. Examples of DDS based on molecularly imprinted polymers (MIPs) can be found for the three main approaches developed to control the moment at which delivery should begin and/or the drug release rate; i.e., rate-programmed, activation-modulated or feedback-regulated drug delivery. This review seeks to highlight the most remarkable advantages of the imprinting technique in the development of new efficient DDS as well as to point out some possibilities of adapting the synthesis procedures to create systems compatible with both the relative instable drug molecules, especially of peptide nature, and the sensitive physiological tissues with which MIP-based DDS would enter into contact when administered. The prospects for future development are also analysed.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1387-2656(06)12007-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26368769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 59

Glucocorticoid action and the development of selective glucocorticoid receptor ligands. 糖皮质激素的作用和选择性糖皮质激素受体配体的发展。

Biotechnology annual review Pub Date : 2006-01-01 DOI: 10.1016/S1387-2656(06)12008-6

Timothy J Cole

{"title":"Glucocorticoid action and the development of selective glucocorticoid receptor ligands.","authors":"Timothy J Cole","doi":"10.1016/S1387-2656(06)12008-6","DOIUrl":"https://doi.org/10.1016/S1387-2656(06)12008-6","url":null,"abstract":"Glucocorticoids are important endocrine regulators of a wide range of physiological systems ranging from respiratory development, immune function to responses to stress. Glucocorticoids in cells activate the cytoplasmic glucocorticoid receptor (GR) that dimerizes, translocates to the nucleus and functions as a ligand-dependent transcriptional regulator. Synthetic glucocorticoids such as dexamethasone and prednisolone have for decades been the cornerstone for the clinical treatment of inflammatory diseases, such as rheumatoid arthritis and asthma, and in some lymphoid cancers, yet its prolonged use has undesirable side effects such as obesity, diabetes, immune suppression and osteoporosis. Detailed knowledge on the mechanism of GR action has led to the development of novel selective glucocorticoid receptor modulators (SGRMs) that show promise of being efficacious for specific treatments of disease but with fewer side effects. SGRMs promote specific recruitment of transcriptional co-regulators that elicit specific gene responses and show promise of greater efficacy and specificity in treatment of inflammatory diseases and type-2 diabetes.","PeriodicalId":79566,"journal":{"name":"Biotechnology annual review","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1387-2656(06)12008-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26368699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 56